VC Funding in Life Sciences Plummets in Q2, Report Finds | GenomeWeb

NEW YORK (GenomeWeb News) – Venture capital investments into the life sciences dropped sharply in the second quarter compared to a year ago, according to a report this week from PricewaterhouseCoopers and the National Venture Capital Association.

VC funding into the life sciences sector, which includes biotechnology and medical devices, was down 39 percent year over year in dollar amounts and down 22 percent in the number of deals. A total of $1.4 billion was invested into 174 life science deals in the second quarter, the report said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

CBC Marketplace commissions DNA testing of chicken sandwiches at Subway and other fast-food chains.

In a speech to Congress, President Donald Trump called the drug approval process at FDA "slow and burdensome."

In Genome Research this week: algorithm to tease out strains from metagenomic sequences, drug resistance mechanisms in cancer cells, and more.

Variants in the IFITM3 gene affect inflammatory response to infection, UPI reports.